Author

Kyle Norcoss

University of Pittsburgh

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:human· 1 Assay:proteomics· 1 Approach:statistical model· 1

Frequent Co-Authors

Ioannis K. ZervantonakisiD· 1 shared Jacob McDonald· 1 shared Matthew D. PoskusiD· 1 shared Matthew S. LairdiD· 1 shared Ruxuan LiiD· 1 shared

Activity by Year

2024-2024 · peak 1/yr

Co-Author Collaboration Network

5 top collaborators · 10 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperBioengineering

Ioannis K. ZervantonakisORCID

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Rational design of HER2-targeted combination therapies to reverse drug resistance in fibroblast-protected HER2+ breast cancer cells.

Matthew D. Poskus, Jacob McDonald, Matthew S. Laird, Ruxuan Li, Kyle Norcoss, Ioannis K. Zervantonakis

This study identifies PAI1 and PLK1 as predictors of fibroblast-mediated resistance in HER2+ breast cancer and shows that targeting these proteins with lapatinib improves treatment efficacy.

Cellular and Molecular Bioengineering · Oct 1, 2024Peer-reviewedBioengineering